The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis
Open accessAbstract
MicroRNA-122 (miR-122), which accounts for 70% of the liver's total miRNAs, plays a pivotal role in the liver. However, its intrinsic physiological roles remain largely undetermined. We demonstrated that mice lacking the gene encoding miR-122a (Mir122a) are viable but develop temporally controlled steatohepatitis, fibrosis, and hepatocellular carcinoma (HCC). These mice exhibited a striking disparity in HCC incidence based on sex, with a male-to-female ratio of 3.9:1, which recapitulates the disease incidence in humans. Impaired expression of microsomal triglyceride transfer protein (MTTP) contributed to steatosis, which was reversed by in vivo restoration of Mttp expression. We found that hepatic fibrosis onset can be partially attributed to the action of a miR-122a target, the Klf6 transcript. In addition, Mir122a(-/-) livers exhibited disruptions in a range of pathways, many of which closely resemble the disruptions found in human HCC. Importantly, the reexpression of miR-122a reduced disease manifestation and tumor incidence in Mir122a(-/-) mice. This study demonstrates that mice with a targeted deletion of the Mir122a gene possess several key phenotypes of human liver diseases, which provides a rationale for the development of a unique therapy for the treatment of chronic liver disease and HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas
Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., & Ghoshal, K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20982 · Cited by 608
RetractedA SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189 · cited 1×
“A 4-ml mixture of chloroform and methanol was added to create a suspension to allow the extraction of lipids (57).”
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 6×
“The fact that Mir122a –/– mice showed reduced serum cholesterol and TG levels is in agreement with previous reports studying mice that were administered miR-122a antisense oligomers (5, 6).”
InfluentialMammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886
MicroRNA targets in Drosophila
Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003) · Genome Biology · doi:10.1186/gb-2003-5-1-r1 · Cited by 3,597 · cited 1×
“Three computational tools, namely miRanda (58), TargetScanS (59), and”
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355 · cited 2×
“MicroRNA 122 (miR-122) is a dominant hepatocyte-specific miRNA (1, 4).”
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Bartel, D. P. (2018) · Cell · doi:10.1016/j.cell.2018.03.006 · Cited by 3,751
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Hammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
Diversifying microRNA sequence and function
Ameres, S. L., & Zamore, P. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3611 · Cited by 1,175
Mechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 831
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Arzumanyan, A., Reis, H. M. G. P. V., & Feitelson, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3449 · Cited by 800
Lou, G., Song, X., Yang, F., Wu, S., Wang, J., Chen, Z., & Liu, Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0220-7 · Cited by 651
miR-122 – A key factor and therapeutic target in liver disease
Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.004 · Cited by 629
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Szabo, G., & Bala, S. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.87 · Cited by 588
Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
Yang, Y., Kim, S., & Seki, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676806 · Cited by 449
Lipid Metabolism, Apoptosis and Cancer Therapy
Huang, C., & Freter, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16010924 · Cited by 444
Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications
Wong, C.-M., Tsang, F. H.-C., & Ng, I. O.-L. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.169 · Cited by 424
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Cui, M., Xiao, Z., Wang, Y., Zheng, M., Song, T., Cai, X., Sun, B., Ye, L., & Zhang, X. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1192 · Cited by 369
Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 354
Adult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
Hepatitis C Virus RNA Functionally Sequesters miR-122
Luna, J. M., Scheel, T. K. H., Danino, T., Shaw, K. S., Mele, A., Fak, J. J., Nishiuchi, E., Takacs, C. N., Catanese, M. T., de Jong, Y. P., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.025 · Cited by 332
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
Kalla, R., Ventham, N. T., Kennedy, N. A., Quintana, J. F., Nimmo, E. R., Buck, A. H., & Satsangi, J. (2015) · Gut · doi:10.1136/gutjnl-2014-307891 · Cited by 267
GAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 262
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259
MicroRNAs in Metabolic Disease
Fernández-Hernando, C., Ramírez, C. M., Goedeke, L., & Suárez, Y. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300144 · Cited by 257
The clinical potential of circulating microRNAs in obesity
Ji, C., & Guo, X. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0260-0 · Cited by 257
Willeit, P., Skroblin, P., Moschen, A. R., Yin, X., Kaudewitz, D., Zampetaki, A., Barwari, T., Whitehead, M., Ramírez, C. M., Goedeke, L., et al. (2017) · Diabetes · doi:10.2337/db16-0731 · Cited by 255
Spatial sorting enables comprehensive characterization of liver zonation
Ben-Moshe, S., Shapira, Y., Moor, A. E., Halpern, K. B., & Itzkovitz, S. (2019) · doi:10.1101/529784 · Cited by 205
Spatial sorting enables comprehensive characterization of liver zonation
Ben-Moshe, S., Shapira, Y., Moor, A. E., Manco, R., Veg, T., Bahar Halpern, K., & Itzkovitz, S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0109-9 · Cited by 205
Epigenetic effects of metformin: from molecular mechanisms to clinical implications
Bridgeman, S. C., Ellison, G. C., Melton, P. E., Newsholme, P., & Mamotte, C. D. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13262 · Cited by 190
Mann, D. A. (2014) · Hepatology · doi:10.1002/hep.27131 · Cited by 153
Baran-Gale, J., Kurtz, C. L., Erdos, M. R., Sison, C., Young, A., Fannin, E. E., Chines, P. S., & Sethupathy, P. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00352 · Cited by 120
microRNAs in lipoprotein metabolism and cardiometabolic disorders
Rotllan, N., Price, N., Pati, P., Goedeke, L., & Fernández-Hernando, C. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.025 · Cited by 100
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis
Novák, J., Olejníčková, V., Tkáčová, N., & Santulli, G. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-22380-3_5 · Cited by 95
MicroRNA‐122 regulates polyploidization in the murine liver
Hsu, S., Delgado, E. R., Otero, P. A., Teng, K., Kutay, H., Meehan, K. M., Moroney, J. B., Monga, J. K., Hand, N. J., Friedman, J. R., et al. (2016) · Hepatology · doi:10.1002/hep.28573 · Cited by 84
Self-citationLuna, J. M., Barajas, J. M., Teng, K.-Y., Sun, H.-L., Moore, M. J., Rice, C. M., Darnell, R. B., & Ghoshal, K. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.025 · Cited by 80
NAFLD and HBV interplay - related mechanisms underlying liver disease progression
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M., & Triantos, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965548 · Cited by 70
miRNA regulation of LDL-cholesterol metabolism
Goedeke, L., Wagschal, A., Fernández-Hernando, C., & Näär, A. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.03.007 · Cited by 39
The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration
Lauschke, V. M., Mkrtchian, S., & Ingelman-Sundberg, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.084 · Cited by 29
Suzuki, T., Kikuguchi, C., Nishijima, S., Nagashima, T., Takahashi, A., Okada, M., & Yamamoto, T. (2019) · Development · doi:10.1242/dev.168146 · Cited by 28
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
MicroRNA-124 promotes hepatic triglyceride accumulation through targeting tribbles homolog 3
Liu, X., Zhao, J., Liu, Q., Xiong, X., Zhang, Z., Jiao, Y., Li, X., Liu, B., Li, Y., & Lu, Y. (2016) · Scientific Reports · doi:10.1038/srep37170 · Cited by 25
Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Metadata
- Authors
- Tsai, W.-C., Hsu, S.-D., Hsu, C.-S., Lai, T.-C., Chen, S.-J., Shen, R., Huang, Y., Chen, H.-C., Lee, C.-H., Tsai, T.-F., Hsu, M.-T., Wu, J.-C., Huang, H.-D., Shiao, M.-S., Hsiao, M., & Tsou, A.-P.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-08-01
- Volume
- 122
- Issue
- 8
- Pages
- 2884-2897
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2029426792
- Cited by
- 814
- References
- 61
- FWCI
- 24.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.